Animal Research

In his Commentary entitled "Animal Rights (And Wrongs)" [The Scientist, Oct. 29, 1990, page 16], Albert Kligman first says we should give the animal rights movement "due credit" for improved conditions for animals in the laboratories and a "drastic reduction" in the number of animals used in biomedical research. These dubious claims of improvements are simply not substantiated in fact. Then he attacks the real successes achieved by the movement, including PETA's [People for the Ethical Treatme

Written byRenate Strauss
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Then he attacks the real successes achieved by the movement, including PETA's [People for the Ethical Treatment of Animals] successful campaigns for alternatives to animals in product testing. "Its [PETA's] aggressive PR stunts have caused Avon, Revlon, and Estee Lauder to forswear the use of animals." By promising only in vitro testing, Kligman fumes, these companies have "improved their public image, while harming the cause of biomedical research."

Kligman's affiliation with the research facilities of L'Oreal at Aulnay-sus-Bois--a company still adamantly opposed to alternatives to animal testing--makes one wonder whether it is "the cause of biomedical research" or the protection of his own business interests that lies behind his condemnation of these successful consumer campaigns to stop animal testing of cosmetics and other nonessential products.

It is curious that Kligman seems to equate biomedical research with product testing. While it may be strategically advantageous to muddle the distinctions between the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies